Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT04849754

Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy

Conditions: Cardiac Amyloidosis

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 30
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche

Location: Hôpital privé Le Bois Lille

Summary

Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR from other amyloidosis or normal patients but fails to evaluate amyloid burden and patient prognosis. Although semi-quantitative methods have been suggested to evaluate the amyloid burden, there a need for quantitative methods for longitudinal assessment of the disease.

Eligibility Criteria

Inclusion Criteria: * Patient, male or female, over 18 years of age * Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy * Patient with signed consent Exclusion Criteria: * Patients with systemic AL amyloidosis * Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant or breastfeeding woman

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04849754). StuddyBuddy aggregates publicly available trial information.